N-[2-(1,3-benzodioxol-5-yl)ethyl]-1-[2-(1H-imidazol-1-yl)-6-methylpyrimidin-4-yl]-D-prolinamide

This compound is a synthetic small molecule belonging to the class of proline derivatives. It is known by the code name BBS‑4 and has been referenced in chemical and pharmacological databases but does not have any approved medical indications or clinical trial activity beyond preclinical or early research phases. The structure features a benzodioxole group linked via an ethylene bridge to a substituted pyrimidine ring with an imidazole moiety and D-prolinamide backbone. There is no evidence of regulatory approval or advanced clinical development for this molecule as of now. Its mechanism of action and therapeutic targets are not described in public sources[1][7][8].

Other names

(2R)-N-[2-(1,3-benzodioxol-5-yl)ethyl]-1-(2-imidazol-1-yl-6-methylpyrimidin-4-yl)pyrrolidine-2-carboxamide(R)-1-(2-(1H-imidazol–1–yl)-6-methylpyrimidin–4–yl)-N-(2-(benzo[d][1,3]dioxol–5–yl)ethyl)pyrrolidine–2-carboxamide2-Pyrrolidinecarboxamide, N-[2-(1,3-benzodioxol–5–yl)ethyl] – 1 – [ 2 – ( 1 H – imidazol – 1 – yl ) – 6-Methyl -4-pyrimidin yl ]-, ( 2 R )